ReviewCurrent opinion in chemical biology2009
Recent development in carbohydrate-based cancer vaccines.
Review in Current opinion in chemical biology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 148 citations in OpenAlex.
- Fluorinated carbohydrate-based vaccines.Chemical science · 2026Review
- Synthetic O-Polysaccharide Backbone Units for a Single Antigen Vaccine Against Two Major Non-Typhoidal Salmonella Serovars.Angewandte Chemie (International ed. in English) · 2026Article
- A Biomimetic Self-Adjuvanting Glycoprotein Vaccine Platform Elicits Potent Antitumor Immunity against GD2-Positive Cancers.JACS Au · 2026Article
- Synthesis and immunological evaluation of the lipopolysaccharide outer core ofChemical science · 2025Article
- Targeting Siglec-Sialylated MUC1 Immune Axis in Cancer.Cancers · 2024Review
- Cancer cells and viruses share common glycoepitopes: exciting opportunities toward combined treatments.Frontiers in immunology · 2024Review
- A Shiga Toxin B-Subunit-Based Lectibody Boosts T Cell Cytotoxicity towards Gb3-Positive Cancer Cells.Cells · 2023Article
- Structure Guided Design of Bacteriophage Qβ Mutants as Next Generation Carriers for Conjugate Vaccines.ACS chemical biology · 2022Article
- Rhamnose-Containing Compounds: Biosynthesis and Applications.Molecules (Basel, Switzerland) · 2022Review
- Synthesis and Glycosidation of Anomeric Halides: Evolution from Early Studies to Modern Methods of the 21st Century.Chemical reviews · 2022Review
- GANAB andInternational journal of molecular sciences · 2022Review
- Design and Synthesis of Bovine Leukemia Virus-Associated Peptide-Based Qβ Conjugate Eliciting Long-Lasting Neutralizing Antibodies in Mice.ACS infectious diseases · 2022Article
- Dendrimers for cancer immunotherapy: Avidity-based drug delivery vehicles for effective anti-tumor immune response.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- Isolipoic acid-linked gold nanoparticles bearing the thomsen friedenreich tumor-associated carbohydrate antigen: Stability andFrontiers in chemistry · 2022Article
- Glycoconjugate Nanoparticle-Based Systems in Cancer Immunotherapy: Novel Designs and Recent Updates.Frontiers in immunology · 2022Review
- A Stable Gold Nanoparticle-Based Vaccine for the Targeted Delivery of Tumor-Associated Glycopeptide Antigens.ACS bio & med chem Au · 2021Article
- Biomolecular Recognition of the Glycan Neoantigen CA19-9 by Distinct Antibodies.Journal of molecular biology · 2021Article
- Discovery of Semi- and Fully-Synthetic Carbohydrate Vaccines Against Bacterial Infections Using a Medicinal Chemistry Approach.Chemical reviews · 2021Review
- Syntheses of Salmonella Paratyphi A Associated Oligosaccharide Antigens and Development towards Anti-Paratyphoid Fever Vaccines.Chemistry (Weinheim an der Bergstrasse, Germany) · 2020Article
- Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Tumor-associated carbohydrate antigens (TACAs) are important molecular markers on the cancer cell surface, useful for the development of therapeutic cancer vaccines or cancer immunotherapies. However, because of their poor immunogenicity and/or immunotolerance, most TACAs fail to induce T cell-mediated immunity that is critical for cancer therapy. This review summarizes the recent effort to overcome this problem via constructing TACA conjugates with improved immunogenicity, such as by covalently coupling TACAs to proper carrier molecules to form clustered or multi-epitopic conjugate vaccines, coupling TACAs to a T cell peptide epitope and/or an immunostimulant epitope to form fully synthetic multi-component glycoconjugate vaccines, and developing vaccines based on chemically modified TACAs, which is combined with metabolic engineering of cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.